



Therapeutic Drug Monitoring (TDM) Guidelines in Blood for Pediatrics and Adults

***NOTE:** **Red** indicates therapeutic or toxic values flagged in the lab and hospital information systems. **Blue** indicates ranges and information included in the interpretation statement.

Drug	Peak/ Trough	Sampling Time	Therapeutic Values	Toxic Values	Time to Steady State
			Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	
Acetaminophen ^{1,5} (Tylenol®) <i>Therapeutic Drug Monitoring</i>	---	2 hours post dose	5-20 µg/mL	>50 µg/mL	Peak: 1-2 hours
Acetaminophen ^{1,5} (Tylenol®) <i>Possible Overdose</i>	---	4 hours post dose	---	>50 µg/mL <u>Additional information:</u> Serious toxicity occurs >200 ug/mL.	
	---	12 hours post dose	---	>50 µg/mL	
Amikacin ^{7,9} (Amikin®)	Peak	30-60 minutes post IV infusion 60-90 minutes post IM injection	20-35 µg/mL <u>Additional information:</u> For most infections, 20-35 µg/mL is recommended. Some serious infections may require a peak range of 28-35 µg/mL.	>35 µg/mL	Neonate: 10-45 hours Child: 3-13 hours Adult: 10-15 hours
	Trough	Within 30 minutes before next dose	0-3 µg/mL <u>Additional information:</u> For most infections, <4 µg/mL is recommended. For severe infections, 4-8 µg/mL may be acceptable, with guidance from an infectious disease specialist.	>9 µg/mL	
	Random	Daily dosing: 8-12 hours after dose	4-35 µg/mL	>35 µg/mL	
Amitriptyline ³ (Elavil®)	Trough	10-14 hours post dose	Total Amitriptyline + Nortriptyline: 120-250 ng/mL	Total Amitriptyline + Nortriptyline: >500 ng/mL	Adult: 3-8 days
Amitriptyline is reported as the total concentration of Amitriptyline and Nortriptyline (metabolite of Amitriptyline). See Nortriptyline for more information.					
Carbamazepine ^{2,9} (Tegretol®)	Trough	Before next dose	4-12 µg/mL <u>Additional information:</u> Single drug regimen: 4-12 µg/mL Multiple drug regimen: 4-8 µg/mL	>15 µg/mL <u>Additional information:</u> Single Drug Regimen: >15 µg/mL Multiple drug regimen: >8 µg/mL Serious toxicity occurs >50 µg/mL.	Variable due to autoinduction Adult: 2-4 days



Therapeutic Drug Monitoring (TDM) Guidelines in Blood for Pediatrics and Adults

***NOTE:** **Red** indicates therapeutic or toxic values flagged in the lab and hospital information systems. **Blue** indicates ranges and information included in the interpretation statement.

Drug	Peak/ Trough	Sampling Time	Therapeutic Values	Toxic Values	Time to Steady State
			Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	
Carbamazepine, Free ^{2,9}	Trough	Before next dose	Free: 0.6-4.1 µg/mL Bound: 66-84%	Not established	(Note: 2)
Clorazepate ^{1,9} (Tranxene®)	Trough	Before next dose	Monitored as the metabolite, Nordiazepam, only. See Nordiazepam for more information.		Adult: 8-21 days (Note: 2)
Cyclosporine ^{8,19}	Trough	≤6 months post-transplant	225-338 ng/mL	Indicating non-compliance: <20 ng/mL Toxic: >450 ng/mL	Varies by patient and type of transplant
		>6 months post-transplant	90-225 ng/mL		
		≤1 month post LIVER transplant	315-405 ng/mL		
		2-6 months post LIVER transplant	225-315 ng/mL		
		>6 months post LIVER transplant	153-216 ng/mL		
		≤6 weeks post CARDIAC transplant:	270-378 ng/mL		
		6-12 weeks post CARDIAC transplant:	162-270 ng/mL		
		>12 weeks post-CARDIAC transplant:	108-162 ng/mL		
Desipramine ^{3,9} (Norpramin®)	Trough	≥12 hours post dose	150-250 ng/mL	>500 ng/mL	Adult: 4-19 days (Note: 2)
Diazepam ^{1,9} (Valium®)	Trough	Before next dose	200-1000 ng/mL	Not established	Adult: 13-56 days (Note: 2)
		Based on normal dosage amounts	Nordiazepam and Oxazepam (metabolites of Diazepam) are reported with Diazepam. See Nordiazepam and Oxazepam for more information.		
Digoxin ^{1,4} (Lanoxin®)	---	Adults: >6 hours, post dose	0.8-2.0 ng/mL	0-10 years: >3.0 ng/mL >10 years: >2.5 ng/mL	Adult: 5-7 days
		Pediatric: Before next dose	<u>Additional information:</u> Congestive Heart Failure: 0.8-1.5 ng/mL Arrhythmia: 1.5-2.0 ng/mL Concurrent use of Quinidine, DigiFab, and DigiBind will elevate the Digoxin level.		
Doxepin ³ (Sinequan®, Adapin®)	---	10-14 hours post dose	Total Doxepin + Nordoxepin: 150-250 ng/mL	Total Doxepin + Nordoxepin: >500 ng/mL	Adult: 2-8 days
		Doxepin is reported as the total concentration of Doxepin and Nordoxepin (metabolite of Doxepin).			



Therapeutic Drug Monitoring (TDM) Guidelines in Blood for Pediatrics and Adults

***NOTE:** **Red** indicates therapeutic or toxic values flagged in the lab and hospital information systems. **Blue** indicates ranges and information included in the interpretation statement.

Drug	Peak/ Trough	Sampling Time	Therapeutic Values	Toxic Values	Time to Steady State
			Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	
Lidocaine ⁴ (Xylocaine®)	----	<30 minutes post IV dose	1.5-5.0 µg/mL	>6.0 µg/mL <u>Signs and symptoms of toxicity:</u> CNS, Cardiovascular depression: 6.0-8.0 µg/mL Seizures, obtundation, decreased cardiac output: >8.0 µg/mL	Adult: 0.5-1.5 hours with loading dose 5-10 hours without loading dose
Lithium ³ (Eskalith®)	Trough	6-12 hours post dose	0.6-1.2 mmol/L	>1.5 mmol/L	Adult: 4-6 days
Mephobarbital ¹⁹	Trough	Before next dose	Monitored as the metabolite, Phenobarbital, only. See Phenobarbital for more information.		
Methadone ⁹ (Dolophine®)	Trough	Single dose	30-80 ng/mL	>2,000 ng/mL <u>Additional information:</u> Interpret with caution as therapeutic and toxic ranges have significant overlap due to large variation in patient opioid tolerance.	Adult: 3-5 days (Note: 2)
Maintenance		200-1,100 ng/mL			
Methotrexate ^{9,10} (Rheumatrex, Folex)	Trough	Low Dose: 1-2 weeks post	See toxic values: Varies with time and dose	>0.02 µmol/L	Adult: 2-3 days (Note: 2)
		High Dose: 24 hours post		≥5.00 µmol/L	
		High Dose: 48 hours post		≥0.50 µmol/L	
		High Dose: 72 hours post		0.05 µmol/L	
Nordiazepam ¹⁹ (metabolite of Diazepam)	Trough	Before next dose Based on normal dosage amounts	60-1800 ng/mL	>2500	8-41 days (Note: 2)
Nortriptyline ⁹ (Aventyl®)	Trough	10-14 hours post dose	50-150 ng/mL	>500 ng/mL	Adult: 4-19 days (Note: 2)
Oxazepam ¹⁹ (Serax®)	Trough	Before next dose Based on normal dosage amounts	200-1400 ng/mL	>2000 ng/mL	1-3 days (Note: 2)
Pentobarbital ⁹ (Nembutal®)	Trough	Before next dose	Sedation: 1-5 µg/mL Intracranial pressure therapy: 30-40 µg/mL Therapeutic coma: 20-50 µg/mL	>10 µg/mL (Sedation)	Adult: 3-6 days (Note: 2)



Therapeutic Drug Monitoring (TDM) Guidelines in Blood for Pediatrics and Adults

***NOTE:** **Red** indicates therapeutic or toxic values flagged in the lab and hospital information systems. **Blue** indicates ranges and information included in the interpretation statement.

Drug	Peak/ Trough	Sampling Time	Therapeutic Values	Toxic Values	Time to Steady State
			Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	
Phenobarbital ² (Luminal®)	Trough	Before next dose	15-40 µg/mL	<1 year: >40 µg/mL (Serious toxicity occurs >60 µg/mL.) ≥1 year: >40 µg/mL <u>Signs and symptoms of toxicity:</u> Slowness, ataxia nystagmus: 35-80 µg/mL Coma with reflexes: 65-117 µg/mL Coma without reflexes (serious): >100 µg/mL	Newborn: 0-4 weeks: 21-28 days 1-12 months: 12-14 days Child: 10-29 days Adult: 10-29 days (Note: 2)
Phenytoin ² (Dilantin®)	Trough	Before next dose Minimum times for collection post dose, IM: >4 hours; IV: >2 hours.	0-3 months: 6-11 µg/mL >3 months: 10-20 µg/mL	>30 µg/mL Serious toxicity occurs >160 µg/mL.	1-3 weeks
Phenytoin, Free	Trough	Before next dose	Free: 1.0-2.0 µg/mL Bound: 85-95%	Free: >3.0 µg/mL Bound: Not established	
Primidone ^{2,9} (Mysoline®)	Trough	Before next dose	5-12 µg/mL	>15 µg/mL Serious toxicity occurs >40 µg/mL.	Adult: 16-64 hours (Note: 2)
Phenobarbital (metabolite of Primidone) is reported with Primidone. See Phenobarbital for more information.					
Salicylates ⁹	Trough	Before next dose	2.0-10.0 mg/dL <u>Additional information:</u> Analgesia, antipyresis: 2.0-10.0 mg/dL Anti-inflammatory: 15.0-30.0 mg/dL	>10.0 mg/dL <u>Signs and symptoms of toxicity:</u> Gastric intolerance, impaired homeostasis: >10.0 mg/dL Deafness, headache, vertigo, tinnitus: 15.0-30.0 mg/dL Nausea, vomiting, hyperventilation: 25.0-40.0 mg/dL Intoxication: >50.0 mg/dL	Adult: 12-15 hours (Note: 2)
Sirolimus ¹⁹ (Rapamycin, Rapamune®)	Trough	Before next dose	3.0-20.0 ng/mL	>20.0 ng/mL	10-16 days (Note: 2)



Therapeutic Drug Monitoring (TDM) Guidelines in Blood for Pediatrics and Adults

***NOTE:** **Red** indicates therapeutic or toxic values flagged in the lab and hospital information systems. **Blue** indicates ranges and information included in the interpretation statement.

Drug	Peak/ Trough	Sampling Time	Therapeutic Values	Toxic Values	Time to Steady State
			Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	
Tacrolimus ¹² (FK506, Prograf®)	Trough	12 hours post-transplant	5.0-20.0 ng/mL The therapeutic range is not clearly defined, but a target. Higher concentrations are associated with an increased incidence of adverse effects.	Not established	Child: 1-2 days Adult: 2-4 days
		≥24 hours post-transplant	3.0-13.0 ng/mL	Not established	
Temazepam ¹⁹	Trough	Before next dose	Not established	Not established	1-4 days (Note: 2)
		Oxazepam (metabolite of Temazepam) is reported with Temazepam. See Oxazepam for more information.			
Theophylline ^{1,6}	Trough	Varies with type of administration. (Note: 1)	0-5 months: 6-11 µg/mL >5 months: 8-20 µg/mL	0-5 months: >14 µg/mL >5 months: >20 µg/mL	Premature: 6 days Newborn: 5 days Infant: 1-5 days Child: 1-2 days Adult: 2-3 days
Tobramycin ⁹ (Nebcin®)	Peak	Post IV infusion: 30 minutes after the end of 30-minute infusion, or immediately after 60 minute infusion post IM infusion: 60-90 minutes NICU: 30 minutes after the end of 30-minute infusion	5.0-8.0 µg/mL <u>Additional information:</u> For most infections, 5.0-8.0 µg/mL is recommended. For severe infections, 8.0-10.0 µg/mL may be acceptable, with guidance from an infectious disease specialist. For synergy against gram positive infections, a range of 3.0-5.0 µg/mL is recommended.	>10.0 µg/mL	Adult: 10-15 hours
	Trough	Within 30 minutes before next dose	0.0-0.9 µg/mL <u>Additional Information:</u> For most infections, <1 µg/mL is recommended. For certain severe infections, <2 µg/mL may be acceptable, with guidance from an infectious disease specialist.	>2.0 µg/mL	
	12 Hour	Daily Dosing: 8-12 hours after dose	0.0-3.4 µg/mL	>3.4 µg/mL	



Therapeutic Drug Monitoring (TDM) Guidelines in Blood for Pediatrics and Adults

***NOTE:** **Red** indicates therapeutic or toxic values flagged in the lab and hospital information systems. **Blue** indicates ranges and information included in the interpretation statement.

Drug	Peak/ Trough	Sampling Time	Therapeutic Values	Toxic Values	Time to Steady State
			Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	Red = Flagged L or H by Cerner/ EPIC Blue = Included in Interpretation Statement	
Topiramate ² (Topamax®)	Trough	Before next dose	5-20 µg/mL	>40 µg/mL <u>Additional information:</u> Not well established. Lab will notify providers of potential toxicity for values >40 µg/mL.	4-5 days
Valproic Acid ² , Total (Depakene®)	Trough	Before next dose	50-120 µg/mL	>120 µg/mL Seizure control may improve at levels over 100 µg/mL, but toxicity may occur at levels of 100-150 µg/mL in some patients. Serious toxicity occurs >200 µg/mL.	Newborn: 41 hours Child: 41-55 hours Adult: 41-74 hours
			Free: 2.0-20.0 µg/mL Bound: 80-95%	Not established	
Vancomycin ^{1,7,8} (Vancocin®)	Peak	Approximately 2 hours after a 60 minute infusion	20-40 µg/mL	>49 µg/mL	Adult: 24-39 hours (Note: 2)
	Trough	Within 30 minutes before next dose	10-20 µg/mL <u>Additional information:</u> For complicated infections (i.e., endocarditis, osteomyelitis, meningitis, and hospital-acquired pneumonia caused by MRSA) or MRSA with an MIC >1 µg/mL, 15-20 µg/mL is recommended. For all other infections, 10-15 µg/mL is recommended.	>25 µg/mL	
	Random	Varies	10-40 µg/mL	>49 µg/mL	

NOTES AND COMMENTS:

- Contact the physician or pharmacy pharmacokinetic specialist for patient-specific information.
- Based on 5 half-lives.⁹



Therapeutic Drug Monitoring (TDM) Guidelines in Blood for Pediatrics and Adults

REFERENCES:

1. Teitz NW, Textbook of Clinical Chemistry, WB Saunders, 3rd edition, 1999, pp 1840-1845.
2. Warner A.; et al; Standards of Laboratory Practice: antiepileptic drug monitoring, Clin. Chem., 1998, 44:5, 1085-1095.
3. Linder M and Keck PE, Standards of Laboratory Practice: antidepressant drug monitoring, Clin. Chem., 1998, 44:5, 1073-1084.
4. Valdes RJ; et al; Standards of Laboratory Practice: cardiac drug monitoring, Clin. Chem., June 2004.
5. White S and Wong SHY, Standards of Laboratory Practice: analgesic drug monitoring, Clin. Chem., 1998, 44:5, 1110-1123.
6. Pesce AJ, et al; Standards of Laboratory Practice: theophylline and caffeine monitoring, Clin. Chem., 1998, 44:5, 1124-1128.
7. Hammett-Stabler CA and Johns T, Laboratory Guidelines for monitoring of antimicrobiol drugs, Clin. Chem., 1998, 44:5, 1129-1140.
8. University of Cincinnati Hospital Transplant Program, Personal Communication, March 1995.
9. Tietz NW, editor; Clinical Guide to Laboratory Tests, Section III, Therapeutic drugs, 1995, pp. 787-897.
10. McEvoy GK, editor, AHFS Drug Information, ASH-SP Press, 1995.
11. Jacobs DS, Laboratory Test Handbook, 4th edition, Lexi-Comp. Inc., 1996.
12. Leiken, J.B.; and Paloucek, F.P.; Poisoning & Toxicology Handbook; 2nd edition., Lexi-Comp, Inc., 1996-1997.
13. Teitz NW, Fundamentals of Clinical Chemistry, Burtis CA and Ashwood ER; WB Saunders, 4th edition, 1999, page 825.
14. Fishman DN, Once-Daily Dosing of Aminoglycoside Antibiotics, Infectious Disease Clinics of North America, 2000; 14:475-487.
15. Karem CM et al, Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments, Pharmacotherapy 1999; 19:257-267.
16. Perry J, Pharm D; Personal Communication; Legacy Good Samaritan Hospital Pharmacy; July 2002.
17. Cole E, et al, Recommendations for the Implementation of Neoral™ C2 Monitoring in Clinical Practice, Transplantation 73(9): S19-S22 and S1-S18, 2002.
18. Levy G, C2 Monitoring Strategy for Optimising Cyclosporine Immunosuppression from the Neoral™ Formulation, BioDrugs 15(5): 279-290, 2001.
19. Brunton LL, Lazo JS, Parker KL, Goodman & Gilman's The Pharmacological Basis of THERAPEUTICS, McGraw-Hill, 11th edition, 2006, pages 1794-1888.